Fig. 1: Risk stratification in multiple myeloma.
From: Current risk stratification and staging of multiple myeloma and related clonal plasma cell disorders
An evolving paradigm of risk stratification for multiple myeloma involves comprehensive tumor genomics evaluation, consideration for disease burden and location, and various host factors that can determine access and response to existing treatments (Created using Biorender®). ISS international staging system, IMWG International Myeloma Working Group, FISH fluorescence in situ hybridization, MRD measurable residual disease, PCL plasma cell leukemia.
